Emmanuel Deau

Roscoff, 29680, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.

Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.

Journal: ACS pharmacology & translational science
Published: February 04, 2026

Nitrogen-Doped Graphene Quantum Dots Conjugated to Leucettinib-21 Rescue Differentiating Zebrafish Purkinje Cells by Inhibiting Dyrk1A Kinase.

Nitrogen-Doped Graphene Quantum Dots Conjugated to Leucettinib-21 Rescue Differentiating Zebrafish Purkinje Cells by Inhibiting Dyrk1A Kinase.

Journal: ACS applied nano materials
Published: January 16, 2026

Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury.

Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury.

Journal: bioRxiv : the preprint server for biology
Published: September 03, 2025

DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes.

DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes.

Journal: Molecular metabolism
Published: August 04, 2025

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome.

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome.

Journal: Science translational medicine
Published: January 24, 2024

Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.

Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.

Journal: Journal of medicinal chemistry
Published: December 05, 2023

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia.

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia.

Journal: Haematologica
Published: September 13, 2023

Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.

Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.

Journal: Journal of medicinal chemistry
Published: July 24, 2023

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

Journal: Journal of medicinal chemistry
Published: March 06, 2023

Serodolin, a β-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors.

Serodolin, a β-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 20, 2022

Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.

Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.

Journal: Journal of medicinal chemistry
Published: December 20, 2021

Organocatalytic enantioselective synthesis of β-amino sulfonic acid derivatives.

Organocatalytic enantioselective synthesis of β-amino sulfonic acid derivatives.

Journal: Chemical communications (Cambridge, England)
Published: August 02, 2021
Showing 1-12 of 16

Last Updated: 09/26/2026